Kim L. Mercer

7.0k citations

15 papers · 3.9k indexed · 3 hit papers · h-index 10

Molecular Biology top 2%
Oncology top 2%
Cancer Research top 2%
Pulmonary and Respiratory Medicine top 5%
Immunology top 10%

Co-authors: Tyler Jacks Roderick T. Bronson Denise Crowley David A. Tuveson Nicholas A. Willis Erica L. Jackson R Montoya Doron C. Greenbaum
Topics: Cancer-related Molecular Pathways (5 papers)RNA modifications and cancer (3 papers)Epigenetics and DNA Methylation (2 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United States Germany

In The Last Decade

Kim L. Mercer

15 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras

2001 1.4k citations Erica L. Jackson, Nicholas A. Willis et al. Genes & Development profile →
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

2001 906 citations Leisa Johnson, Kim L. Mercer et al. Nature profile →
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

2004 626 citations David A. Tuveson, Alice T. Shaw et al. Cancer Cell profile →

Peers

Countries citing papers authored by Kim L. Mercer

Since Specialization

Citations

This map shows the geographic impact of Kim L. Mercer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim L. Mercer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim L. Mercer more than expected).

Fields of papers citing papers by Kim L. Mercer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim L. Mercer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim L. Mercer. The network helps show where Kim L. Mercer may publish in the future.

Co-authorship network of co-authors of Kim L. Mercer

This figure shows the co-authorship network connecting the top 25 collaborators of Kim L. Mercer. A scholar is included among the top collaborators of Kim L. Mercer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim L. Mercer. Kim L. Mercer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells 2022 ·Nature Communications ·(unknown),Rodrigo Romero,Emma V. Watson,Anthony C. Liang,Megan L. Burger,Peter M.K. Westcott,Kim L. Mercer,Roderick T. Bronson,Eric C. Wooten,Arjun Bhutkar,Tyler Jacks,Stephen J. Elledge	9
2	Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells 2020 ·Molecular Oncology ·(unknown),(unknown),Diana Mendus,Ralf A. Hilger,Trudy G. Oliver,Kim L. Mercer,Björn-Oliver Gohlke,Kati Erdmann,Dieter Niederacher,Hans Neubauer,Paul Buderath,Pauline Wimberger,Jan Dominik Kuhlmann,Jürgen Thomale	7
3	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1 2020 ·Nature Cancer ·Rodrigo Romero,Francisco J. Sánchez‐Rivera,Peter M.K. Westcott,Kim L. Mercer,Arjun Bhutkar,Alexander Muir,Tania J González-Robles,(unknown),(unknown),Sheng Rong Ng,Leanne Li,Caterina I. Colón,Santiago Naranjo,Mary C. Beytagh,Caroline A. Lewis,Peggy P. Hsu,Roderick T. Bronson,Matthew G. Vander Heiden,Tyler Jacks	42
4	The CD155/TIGIT Axis Promotes and Maintains Immune Evasion in Neoantigen-Expressing Pancreatic Cancer 2020 ·SSRN Electronic Journal ·William A. Freed-Pastor,(unknown),Zackery A. Ely,(unknown),Arjun Bhutkar,George Eng,Kim L. Mercer,Ana Patiño‐García,Lin Lin,William M. Rideout,William L. Hwang,Jason M. Schenkel,Roderick T. Bronson,Peter M.K. Westcott,Vikram Deshpande,Toni Delorey,Devan Phillips,Ömer Yılmaz,Aviv Regev,Tyler Jacks	8
5	CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer 2019 ·Proceedings of the National Academy of Sciences ·Sheng Rong Ng,William M. Rideout,Elliot H. Akama‐Garren,Arjun Bhutkar,Kim L. Mercer,Jason M. Schenkel,Roderick T. Bronson,Tyler Jacks	58
6	Identification of DHODH as a therapeutic target in small cell lung cancer 2019 ·Science Translational Medicine ·Leanne Li,Sheng Rong Ng,Caterina I. Colón,Benjamin J. Drapkin,Peggy P. Hsu,Zhaoqi Li,Christopher S. Nabel,Caroline A. Lewis,(unknown),Kim L. Mercer,Arjun Bhutkar,Sarah Phat,David T. Myers,Mandar D. Muzumdar,Peter M.K. Westcott,Mary C. Beytagh,Anna F. Farago,Matthew G. Vander Heiden,Nicholas J. Dyson,Tyler Jacks	103
7	Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results 2013 ·Gastrointestinal Endoscopy ·Sonia Gosain,Kim L. Mercer,William S. Twaddell,Lance Uradomo,Bruce D. Greenwald	93
8	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer 2010 ·Genes & Development ·Trudy G. Oliver,Kim L. Mercer,Leanne C. Sayles,James R. Burke,Diana Mendus,Katherine S. Lovejoy,(unknown),Aravind Subramanian,David Mu,Scott Powers,Denise Crowley,Roderick T. Bronson,Charles A. Whittaker,Arjun Bhutkar,Stephen J. Lippard,Todd R. Golub,Jüergen Thomale,Tyler Jacks,E. Alejandro Sweet‐Cordero	7
9	p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis 2009 ·Science ·David G. Kirsch,Philip M. Santiago,Emmanuelle di Tomaso,Julie M. Sullivan,Wu-Shiun Hou,Talya L. Dayton,Laura B. Jeffords,(unknown),Kim L. Mercer,(unknown),Osamu Takeuchi,Stanley J. Korsmeyer,Roderick T. Bronson,Carla F. Kim,Kevin M. Haigis,Rakesh K. Jain,Tyler Jacks	1
10	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defectsbreakdown → 2004 ·Cancer Cell ·David A. Tuveson,Alice T. Shaw,Nicholas A. Willis,Daniel P. Silver,Erica L. Jackson,Sandy Chang,Kim L. Mercer,Rebecca Grochow,Hanno Hock,Denise Crowley,Sunil R. Hingorani,Tal Zaks,Catrina E. King,Michael A. Jacobetz,Lifu Wang,Roderick T. Bronson,Stuart H. Orkin,Ronald A. DePinho,Tyler Jacks	626
11	Targeted Deletion Reveals an Essential Function for the Telomere Length Regulator Trf1 2003 ·Molecular and Cellular Biology ·Jan Karlseder,(unknown),Hiroyuki Takai,Kim L. Mercer,Sunil R. Hingorani,Tyler Jacks,Titia de Lange	129
12	ARF mutation accelerates pituitary tumor development in Rb +/− mice 2002 ·Proceedings of the National Academy of Sciences ·Kenneth Y. Tsai,David MacPherson,Douglas A. Rubinson,Alexander Yu. Nikitin,Roderick T. Bronson,Kim L. Mercer,Denise Crowley,Tyler Jacks	35
13	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasbreakdown → 2001 ·Genes & Development ·Erica L. Jackson,Nicholas A. Willis,Kim L. Mercer,Roderick T. Bronson,Denise Crowley,R Montoya,Tyler Jacks,David A. Tuveson	1392
14	Somatic activation of the K-ras oncogene causes early onset lung cancer in micebreakdown → 2001 ·Nature ·Leisa Johnson,Kim L. Mercer,Doron C. Greenbaum,Roderick T. Bronson,Denise Crowley,David A. Tuveson,Tyler Jacks	906
15	K-ras is an essential gene in the mouse with partial functional overlap with N-ras 1997 ·Genes & Development ·Leisa Johnson,Doron C. Greenbaum,Karen Cichowski,Kim L. Mercer,Elizabeth A. Murphy,Eric Schmitt,Roderick T. Bronson,(unknown),(unknown),Raju Kucherlapati,Tyler Jacks	449

About Kim L. Mercer

Kim L. Mercer is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 15 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (5 papers), RNA modifications and cancer (3 papers) and Epigenetics and DNA Methylation (2 papers). The work is most often cited by research in Oncology (1.6k citations), Cancer Research (737 citations) and Molecular Biology (2.6k citations). Kim L. Mercer has collaborated with scholars based in United States and Germany. Frequent co-authors include Tyler Jacks, Roderick T. Bronson, Denise Crowley, David A. Tuveson, Nicholas A. Willis, Erica L. Jackson, R Montoya, Doron C. Greenbaum, Leisa Johnson and Sunil R. Hingorani. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact